Webinar:  CLIA IQCP: Difference from Standard QC Approach, Requirements and Laboratory Compliance

Shire

ShireShire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company's website: www.shire.com.

Shire RSS Channel

Title Filter      Display #  
# Article Title
1 Shire acquires Premacure AB
2 Shire and Boston Children's Hospital enter into broad research collaboration
3 Shire continued strong product sales performance in Q3
4 Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
5 Shire delivers a strong first quarter performance
6 Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
7 Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma
8 Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships
9 Shire Proposes to Expand Specialist Gastrointestinal Portfolio
10 Shire Purchases Strategic Site in Massachusetts
11 VYVANSE® - new ADHD treatment option - now available in Canada
12 FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
13 Shire Limited has changed its name to Shire plc
14 Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million
15 Shire plc accelerating new product sales drive revenue growth of 36%
16 Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]